Menu Back to Real-World-Evidence-Conference


Short Course: October 22
Conference: October 25-26

In a market that is constantly adapting and adjusting to the needs of the healthcare field, real-world evidence (RWE) is increasingly becoming important for regulatory and reimbursement decision-making. RWE, in relation to the real-world data that is collected in combination with the advancement of artificial intelligence-based analytics platforms, has led to the real-time analysis of data to better understand and gain insights on disease, approaches to treatment, and how to substantiate coverage decisions. Historically used for post-market safety monitoring, RWE is now becoming integrated throughout the product development lifecycle. DIA’s Real-World Evidence Conference will explore new and innovative applications of RWE and deliver cutting-edge insights through successful use cases, case examples, and practical applications on how stakeholders are leveraging RWE to advance healthcare knowledge and decision-making.


Want to learn more about Real-World Evidence Conference? You've come to the right site!

Continuing Education

Learn more


Learn more

Highlights & Features

Learn more

Who should attend?

Professionals involved in:

  • Real-World Evidence
  • Real-World Data
  • Epidemiology
  • Policy
  • Regulatory Science
  • Technology development
  • Data analytics
  • Clinical Research

Learning objectives

At the conclusion of this activity, participants should be able to:

  • Explain how RWE is being used today to inform biopharmaceutic development across product lifecycle
  • Discuss “lessons learned” from current uses of RWE by regulators, and how they can be applied for other future applications of RWE
  • Recognize general considerations and key features of successful RWE studies acceptable to the regulators for effective decision-making
  • Identify guidance and best practices for generating fit-for-purpose RWE for payers and HTA bodies
  • Define the expanding applications of RWE to support clinical trials and evidence generation
  • Evaluate the future applications of RWE in drug development
  • Appraise how mobile technologies, artificial intelligence, machine learning, and other technologies are being used to generate RWE
  • Evaluate how patient reported outcomes, electronic health records, and other patient data is expanding the resources for RWE

Program Committee

  • Paul Test Account  Wong
    Paul Test Account Wong Associate Director, Meeting Op
    Drug Information Assoc, United States
  • Brian  Bradbury, DrSc, MA
    Brian Bradbury, DrSc, MA Vice President, Center for Observational Research
    Amgen, United States
  • Dorothee  Bartels, PhD, MSc
    Dorothee Bartels, PhD, MSc Chief Digital Officer
    Aetion, Germany
  • Paul M. Coplan, DrSc, MBA, MSc, FISPE
    Paul M. Coplan, DrSc, MBA, MSc, FISPE VP, Medical Device Epidemiology & Real-World Data Analytics
    Johnson & Johnson, United States
  • Simon  Dagenais, PhD, MSc
    Simon Dagenais, PhD, MSc Real-World Evidence Lead, Internal Medicine
    Pfizer Inc, United States
  • Marni  Hall, PhD, MPH
    Marni Hall, PhD, MPH VP & GM, Global Regulatory Science and Strategy
    IQVIA, United States
  • James  Harnett, PharmD, MS
    James Harnett, PharmD, MS Executive Director, Health Economics and Outcomes Research
    Regeneron Pharmaceuticals, Inc. , United States
  • Jingyu (Julia)  Luan, PhD
    Jingyu (Julia) Luan, PhD Senior Director, Global Regulatory Affairs, BioPharmaceuticals R&D
    AstraZeneca, United States
  • David  Martin, MD, MPH
    David Martin, MD, MPH Vice President, Global Head RWE
    Moderna, United States
  • Delphine  Saragoussi, MD, MSc
    Delphine Saragoussi, MD, MSc Executive Director, Real-World Evidence
    PPD, part of Thermo Fisher Scientific, France
  • Mark  Stewart, PhD
    Mark Stewart, PhD Vice President, Science Policy
    Friends of Cancer Research, United States
  • Sulabha  Ramchandran, PhD, MS
    Sulabha Ramchandran, PhD, MS Vice President and Head, US and Regions, Value Evidence and Outcomes
    GlaxoSmithKline, United States
  • Yun  Lu, PhD, MS
    Yun Lu, PhD, MS Mathematical Statistician, Office of Biostatistics and Pharmacovigilance, CBER
    FDA, United States
Load More